Acrivon Therapeutics (ACRV) announced that Mansoor Raza Mirza, M.D., has been appointed Chief Medical Officer of the company, effective April 9. With the appointment of Dr. Mirza, the company’s current Chief Medical Officer, Jean-Marie Cuillerot, M.D., will depart the company on April 9.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Buy Rating Reaffirmed for Acrivon Therapeutics Amid Promising Endometrial Cancer Data and Strong Financial Position
- Acrivon Therapeutics price target lowered to $7 from $22 at JonesResearch
- Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer
- Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c)
- Acrivon Therapeutics Reports 2024 Financial Results and Progress